To evaluate the efficacy and safety of SHR-A2102 for injection versus Investigator-selected Therapy in patients with Locally advanced or Metastatic Urothelial Carcinoma who have been previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.
Voluntarily participate in this clinical study, understand the study procedures and be able to sign the informed consent form in writing.
18 to 80 years old (including boundary value), gender is not limited.
ECOG performance status score of 0 or 1.
Estimated survival ≥ 3 months.
Planned to receive any other anti-tumor therapy during this trial.
Receipt of other unmarketed clinical trial drugs or treatments within 4 weeks prior to randomization.
Received systemic anti-tumor therapy such as chemotherapy, radiotherapy, biological therapy, targeted therapy, or immunotherapy within 4 weeks prior to randomization, and palliative radiotherapy or local therapy within 2 weeks prior to the first use of the investigational drug.
Prior receipt of antibody-drug conjugates containing topoisomerase I inhibitors in the composition.